A new study led by the Baltimore based researcher Dr. Rehan Qayyum has revealed that the synthetic version of the human insulin is equally good for the type 2 diabetes.In an interview to the Reuters, Dr. Rehan Qayyum from Johns Hopkins Hospital, said,
“There is no difference between premixed human insulin and premixed insulin analogues.”
The study, published in the Annals of Internal Medicine finds that the Premixed insulin analogues provided tighter glucose control than long-acting insulin and non-insulin agents, according to the investigators’ report in the Annals of Internal Medicine. Premixed insulin analogues were comparable to premixed human insulin in lowering A1C levels, an indicator of relatively long-term glucose control.
The occurrence of episodes of too-low glucose levels, i.e., hypoglycemia, was similar with premixed insulin analogues and with premixed human insulin.
It can be added that the insulin analog is an altered form of insulin different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycemic control. Through genetic engineering of the underlying DNA, amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics.
These modifications have been used to create two types of insulin analogs: those that are more readily absorbed from the injection site and therefore act faster than natural insulin injected subcutaneously, intended to supply the bolus level of insulin needed after a meal; and those that are released slowly over a period of between 8 and 24 hours, intended to supply the basal level of insulin for the day.
However, researchers also told that much research work is required to determine whether the effects are sustainable long term.
Source: Reuters
Filed under Diabetes, NIDDM | Tags: glycemic control, human insulin, insulin analog, long-term glucose control | Comment Below
Related?
Insulin analogue glargine linked to increased cancer risk among diabetes
PatientsJune 27th, 2009 WASHINGTON - Diabetes patients' risk of cancer increases if they use the long-acting insulin analogue glargine instead of human insulin, according to a study. Led by a collaborative team of researchers from the Institute for Quality and Efficiency in Health Care (IQWiG) and a research institute of the German Local Health Care Fund, the study analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues lispro (trade name: Humalog), aspart (Novorapid) or glargine (Lantus) between January 2001 and June 2005.
Pre-mixed insulin works better in post meal sugar control in type 2 patients September 17th, 2008 Johns Hopkins University researchers have found that the Pre-mixed insulin analogues acts better than the conventional pre-mixed human insulin in the type 2 diabetes patients. The report funded by the Healthcare Research and Quality concludes that Pre-mixed insulin analogues helps to lower the sugar level down after meals.
Technosphere Insulin Over Other Treatment RegimensMarch 8th, 2006 Diabetes and cancer treatments developer MannKind has initiated patient enrollment in two pivotal 12-month phase III clinical trials of its Technosphere Insulin in patients with type 1 and type 2 diabetes. The main objective of these studies is to evaluate the efficacy of Technosphere Insulin (TI) by assessing changes both in HbA1c levels as well as in blood glucose levels after a standardized meal.
Diabetes Cure: Human Trial of Type 1 Diabetics With Alginate Coated Islet CellsJanuary 29th, 2007 An Australian company, Living Cell Technologies, will conduct human trial with Islet cells (insulin producing cells from pancreas) taken from pigs and transplanting them into human diabetes patients. The cells will be coated with alginate, a seaweed derivative which has been used with some success earlier with human islet cells in USA.
Insulin producing beta cells a better alternative to organ transplantSeptember 3rd, 2008 Now there is a new hope for type 1 diabetics as the researchers of Tel Aviv University has developed a new cure which is based on beta cell therapy. This beta cell therapy involves the formation of insulin producing beta cells from human tissue outside the human body and then injecting the same cells in the pancreas to make insulin.
R1583 Type 2 Diabetes (NIDDM) Drug Gets Strong RatingMay 30th, 2008 A drug having code number R 1583, a Swiss company's product, is going to mark a significant improvement in the history of medical Diabetes. The drug belongs to a new type group called GLP-1 analogues which aims in treating type 2 diabetes.
Scientists identify new glucose-regulating protein linked with diabetesMay 29th, 2009 WASHINGTON - Scientists have found that a specialized protein in human muscles is linked with the process that clears glucose out of the bloodstream. The finding by researchers at the University of California, San Francisco, and collaborators at Harvard Medical School, could shed light on what goes wrong in type 2 diabetes on a cellular level.
Risk Of Diabetes May Not Be Affected by Trans Fatty AcidsJuly 9th, 2008 According to Beatrice Morio, researcher in the Human Nutrition Unit of the Food and Human Nutrition Research Department in Clermont-Ferrand and his Colleagues, risk of diabetes and insulin resistance are not affected by Trans Fatty acids. To prove this they undergo an experiments on rats.
